Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis
Authors' conclusion
Although the primary endpoint was not met, the data provide important information on baricitinib for the treatment of children with JIA-U refractory to both MTX and bDMARDs. Baricitinib safety profile in this study was consistent with previous studies in children and adults with other diseases.
Study context
- Population
- Pediatric patients with active JIA-associated uveitis or chronic anterior ANA-positive uveitis with inadequate response to methotrexate (MTX) or biologic disease-modifying antirheumatic drugs (bDMARDs)
- Participants
- 30 patients
- Comparison
- Baricitinib vs active reference arm
- Primary endpoint
- Proportion of responders per SUN criteria: two-step decrease in inflammation (anterior chamber cells) or decrease to zero through W24 in the most severely affected eye at baseline; success if >80% posterior probability that baricitinib response rate at W24 was at least 57%
- Follow-up
- Week 24
Methodological detailsopen-label, active-controlled, phase-3, multicentre, 1:1 randomization to an active reference arm, prespecified Bayesian success rule
- Open-label
- Active-controlled
- phase-3
- Multicentre
- 1:1 randomization to an active reference arm
- Prespecified Bayesian success rule
Primary result
As reported in the abstract
SUN criteria responders (two-step decrease in anterior chamber cells or decrease to zero, most severely affected eye) · W24
Patients achieving a response at W24
8
33.3%
Posterior probability of a response rate of >57%
1.03%
Further findings
Two-step decrease in Standardization of Uveitis Nomenclature (SUN) criteria at W24, by prior therapy (baricitinib) · week 24
- MTX-inadequate responder (MTX-IR) and bDMARD-IR patients
- 36.8%
- MTX-IR patients
- 20%
Safety
- Consistent with established safety profile in other baricitinib indications in pediatric and adult patients
Original publication
Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis. Arthritis Care Res (Hoboken). Published 1 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →